These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Glass M; Dragunow M; Faull RL Neuroscience; 2000; 97(3):505-19. PubMed ID: 10828533 [TBL] [Abstract][Full Text] [Related]
6. Insight Into the Emerging Role of Striatal Neurotransmitters in the Pathophysiology of Parkinson's Disease and Huntington's Disease: A Review. Jamwal S; Kumar P Curr Neuropharmacol; 2019; 17(2):165-175. PubMed ID: 29512464 [TBL] [Abstract][Full Text] [Related]
7. Pathophysiology of chorea and bradykinesia in Huntington's disease. Berardelli A; Noth J; Thompson PD; Bollen EL; Currà A; Deuschl G; van Dijk JG; Töpper R; Schwarz M; Roos RA Mov Disord; 1999 May; 14(3):398-403. PubMed ID: 10348461 [TBL] [Abstract][Full Text] [Related]
8. Progress in understanding Huntington's chorea. Barbeau A Can J Neurol Sci; 1975 May; 2(2):81-5. PubMed ID: 124199 [TBL] [Abstract][Full Text] [Related]
9. Role of pallidum in genesis of some choreic movements. SPIEGEL EA; WYCIS HT Neurology; 1953 Apr; 3(4):261-6. PubMed ID: 13054853 [No Abstract] [Full Text] [Related]
13. Hard target: understanding dopaminergic neurotransmission. Nestler EJ Cell; 1994 Dec; 79(6):923-6. PubMed ID: 8001139 [No Abstract] [Full Text] [Related]
14. Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Coyle JT; Schwarcz R Nature; 1976 Sep; 263(5574):244-6. PubMed ID: 8731 [No Abstract] [Full Text] [Related]
15. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea. Huot P; Lévesque M; Parent A Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832 [TBL] [Abstract][Full Text] [Related]
16. Letter: Pathogenesis of Huntington's chorea, Pick's disease, and paralysis agitans. van Wolferen WJ; Bruyn GW; Teepen JL Lancet; 1974 Jun; 1(7866):1112. PubMed ID: 4135274 [No Abstract] [Full Text] [Related]
17. Adenosine A2 receptors: selective localization in the human basal ganglia and alterations with disease. Martinez-Mir MI; Probst A; Palacios JM Neuroscience; 1991; 42(3):697-706. PubMed ID: 1835521 [TBL] [Abstract][Full Text] [Related]
18. Comparison of phosphodiesterase 10A, dopamine receptors D1 and D2 and dopamine transporter ligand binding in the striatum of the R6/2 and BACHD mouse models of Huntington's disease. Miller S; Hill Della Puppa G; Reidling J; Marcora E; Thompson LM; Treanor J J Huntingtons Dis; 2014; 3(4):333-41. PubMed ID: 25575954 [TBL] [Abstract][Full Text] [Related]
19. Striatal calcium channel antagonist receptors in Huntington's disease and Parkinson's disease. Watson DL; Carpenter CL; Marks SS; Greenberg DA Ann Neurol; 1988 Mar; 23(3):303-5. PubMed ID: 2967667 [TBL] [Abstract][Full Text] [Related]
20. Biochemical mechanisms and management of choreiform movement disorders. de Silva L Drugs; 1977 Oct; 14(4):300-10. PubMed ID: 144049 [No Abstract] [Full Text] [Related] [Next] [New Search]